BiotechTube

Sotagliflozin + Placebo

Phase 3Recruiting
0 views this week 0 watching⚡ Active💉Featured in GLP-1 & Metabolic Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Nephropathies

Conditions

Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1, Heart Failure

Trial Timeline

Oct 31, 2024 → May 1, 2029

NCT ID
NCT06217302

About Sotagliflozin + Placebo

Sotagliflozin + Placebo is a phase 3 stage product being developed by Dexcom for Diabetic Nephropathies. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06217302. Target conditions include Diabetic Nephropathies, Kidney Failure, Chronic, Diabetes Mellitus Type 1.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Nephropathies were approved

Approved (20) Terminated (3) Active (0)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag(Sarpogrelate) + PlaceboYuhanApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06217302Phase 3Recruiting

Competing Products

20 competing products in Diabetic Nephropathies

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CHF6467 activeComac MedicalPhase 1/2
22
Ruboxistaurin mesylateEli LillyPhase 3
40
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
Baricitinib + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
Anplag(Sarpogrelate) + PlaceboYuhanApproved
43
CS-3150 + placeboDaiichi SankyoPhase 2
35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
40
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Beraprost sodiumAstellas PharmaPre-clinical
22